Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PRG +9.8%, OTLY +8%, MANH +6.7%, STX +4.9%, FTAI +4.2%, THC +4%, ALKS +4%, ENPH +3.6%, T +3.1%, MTDR +2.9%, ENVA +2.9%, BLX +2.8%, RCI +2.7%, EVR +2.4%, ODFL +2.4%, SAN +2.2%, PKG +2.1%, TXN +2.1%, NEP +1.9%, RRC +1.8%, GEV +1.8%, IPG +1.6%, ORAN +1.4%, CHKP +1.3%, KBR +1.1%, EQT +1%, CB +0.9%, EQNR +0.9%, NEE +0.9%, BSX +0.8%, LPG +0.8% (guidance)
Other news:
- SNDR +6.1% (to join S&P SmallCap 600)
- AVTR +4.8% (to join S&P MidCap 400)
- NUVB +3.7% (announces multiple updates for its taletrectinib program)
- VLN +3.6% (Value Base affirms 18.51% active stake (prior 15.09% passive stake); entered Board Nomination Agreement)
- NKTX +1.5% (initiation of investigator-sponsored clinical trial evaluating NKX019 for systemic lupus erythematosus)
- WDC +1.4% (in sympathy with STX earnings)
- VIGL +1.3% (announces interim data from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers)
- SLND +1.2% (completed a sale-leaseback transaction for three properties)
- CRWD +1.2% (provides preliminary post incident review)
- ESEA +1.1% (announces 18-month charter contract)
- EL +1% (names new CFO; provides Restructuring Program updates; expects to record restructuring and other charges of approximately $137 million)
Analyst comments:
- MSGE +2.6% (upgraded to Buy from Neutral at Goldman)
- SPOT +0.5% (upgraded to Buy from Neutral at Goldman; upgraded to Buy from Hold at DZ Bank)